Cingulate Inc. (CING) Stock Price & Analysis
Cingulate Inc. (CING) fell 4.13% to USD 4.64 as of July 26, 2026 at 12:49 UTC, according to Nexqual real-time market data.
CING last closed at USD 4.84; the session ranged USD 4.55–4.84 on volume of 75,091 shares. Market capitalization is $62.50M, with a 52-week range of USD 3.16–11.89 (NCM). Source: Nexqual, July 26, 2026 at 12:49 UTC.
Key Statistics (as of July 26, 2026 at 12:49 UTC)
| Price | USD 4.64 |
|---|---|
| Change | ▼ 4.13% (down) |
| Previous Close | USD 4.84 |
| Open | USD 4.84 |
| Day Range | USD 4.55 – 4.84 |
| 52-Week Range | USD 3.16 – 11.89 |
| Volume | 75,091 shares |
| Market Cap | $62.50M |
| Exchange | NCM |
Technical Analysis (CING)
Nexqual's technical model rates CING "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 12:49 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.88 (neutral) |
| vs SMA50 | Below (USD 4.75) |
| MACD | -0.07 (negative) |
Analyst Ratings (CING)
Wall Street analysts rate CING "None" based on 5 analysts, with a mean price target of USD 23 (range USD 8–52), per Nexqual as of July 26, 2026 at 12:49 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 23 |
| High Target | USD 52 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (CING)
| EPS Estimate | USD -0.56 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.95 vs est -0.53 ▼ miss |
| 2025-12-31 | USD -0.84 vs est -1.55 ▲ beat |
| 2025-09-30 | USD -1.35 vs est -0.75 ▼ miss |
| 2025-06-30 | USD -1.09 vs est -0.82 ▼ miss |
Source: Nexqual, July 26, 2026 at 12:49 UTC.
Financials & Fundamentals (CING)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -225.11% |
| Debt / Equity | 39.38 |
| Current Ratio | 2.55 |
| Total Cash | $25.89M |
| Total Debt | $7.43M |
| Free Cash Flow | $-11.92M |
Source: Nexqual, July 26, 2026 at 12:49 UTC.
Financial Health Score (CING)
Nexqual rates Cingulate Inc.'s overall financial health "Weak" across five dimensions, as of July 26, 2026 at 12:49 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $26M cash vs $7M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$20M |
| Efficiency | Critical — ROE -225%, ROA -69.7% |
Ownership (CING)
| Insider Ownership | +30.54% |
|---|---|
| Institutional Ownership | +8.94% |
| Shares Outstanding | 13.47M |
| Float | 12.94M |
| Short % of Float | +17.95% |
Source: Nexqual, July 26, 2026 at 12:49 UTC.
Leadership (CING)
Cingulate Inc. is led by Jennifer L. Callahan (age 54), Executive VP, CFO & Secretary, per Nexqual as of July 26, 2026 at 12:49 UTC.
| Executive VP, CFO & Secretary | Jennifer L. Callahan (age 54) |
|---|---|
| Vice President of Investor & Public Relations | Thomas Dalton |
Major Backers & Investors (CING)
Notable institutional backers of Cingulate Inc. include Kestra Advisory Services, LLC, Marshall Wace LLP, Jane Street Group, LLC, according to Nexqual as of July 26, 2026 at 12:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Kestra Advisory Services, LLC | 1.04% |
| Marshall Wace LLP | 0.69% |
| Jane Street Group, LLC | 0.67% |
| Fidelity | 0.63% |
| Xtx Topco Ltd | 0.4% |
| Bcv Asset Management Inc. | 0.38% |
| Quadrature Capital Ltd | 0.26% |
| HRT Financial LP | 0.25% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.95% |
| Geode Capital | 0.75% |
Source: Nexqual, July 26, 2026 at 12:49 UTC.
From Cingulate Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Roberts served as the Chief Financial Officer for VirMedica, Inc., a company that provides an end-to-end platform that enables specialty drug manufacturers and pharmacies to optimize product commercialization and management.
Partnerships
- Schaffer   On September 23, 2021, we entered into an employment agreement with Dr.
- Callahan   On January 25, 2024, we entered into an employment agreement with Ms.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBLG | Bone Biologics Corp | USD 1.07 | ▼ 2.73% |
| DRMA | Dermata Therapeutics, Inc. | USD 1.32 | ▲ 4.76% |
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.55 | ▼ 7.74% |
| SPRC | SciSparc Ltd. | USD 5.33 | ▲ 10.12% |
| VRAX | Virax Biolabs Group Limited | USD 3.19 | ▼ 12.36% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 12:49 UTC. This page is informational and not investment advice.